Benoît You

459 total citations
12 papers, 118 citations indexed

About

Benoît You is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Economics and Econometrics. According to data from OpenAlex, Benoît You has authored 12 papers receiving a total of 118 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 2 papers in Economics and Econometrics. Recurrent topics in Benoît You's work include Health Systems, Economic Evaluations, Quality of Life (2 papers), Statistical Methods in Clinical Trials (2 papers) and Ovarian cancer diagnosis and treatment (2 papers). Benoît You is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (2 papers), Statistical Methods in Clinical Trials (2 papers) and Ovarian cancer diagnosis and treatment (2 papers). Benoît You collaborates with scholars based in France, Australia and United Kingdom. Benoît You's co-authors include Hui Gan, Gregory R. Pond, Christophe Sajous, Julien Péron, Gilles Freyer, Claire Falandry, Gilles Freyer, Marc Bonnefoy, Christophe Le Tourneau and Elisa Fontana and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Annals of Oncology.

In The Last Decade

Benoît You

11 papers receiving 115 citations

Peers

Benoît You

ONCOL

Sharly J. Nass

Tie‐Hua Ng United States

Grace Hsu Canada

Narayanan Srihari United Kingdom

Dena Howard United Kingdom

Bryan Bowser United States

Aneta Suder United Kingdom

Denise Sheehan United Kingdom

Silvia Calderazzo Germany

Tamy Kim United States

Sharly J. Nass

Benoît You

30 ×0.7

59 ×1.7

30 ×1.0

ONCOL

86 ×3.2

17 ×0.7

Citations per year, relative to Benoît You Benoît You (= 1×) peers Sharly J. Nass

Countries citing papers authored by Benoît You

Since Specialization

Citations

This map shows the geographic impact of Benoît You's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benoît You with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benoît You more than expected).

Fields of papers citing papers by Benoît You

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benoît You. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benoît You. The network helps show where Benoît You may publish in the future.

Co-authorship network of co-authors of Benoît You

This figure shows the co-authorship network connecting the top 25 collaborators of Benoît You. A scholar is included among the top collaborators of Benoît You based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benoît You. Benoît You is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Duruisseaux, M., Benjamin Besse, Nicolas Girard, et al.. (2025). IMMUNORARE ⁵ : A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers—The B3 Thymomas and Thymic Carcinomas Cohort.. Journal of Clinical Oncology. 43(16_suppl).

Fontana, Elisa, Marie Robert, Alejandro Falcón, et al.. (2025). Zanzalintinib (XL092) alone or in combination with atezolizumab in patients (pts) with refractory metastatic colorectal cancer (mCRC): Results from an expansion cohort of the phase 1 STELLAR-001 study.. Journal of Clinical Oncology. 43(4_suppl). 127–127. 2 indexed citations

Lim, Myong Cheol, Boram Park, Jung‐Yun Lee, et al.. (2024). Rationale and study design of the KOV-HIPEC-04: A phase III randomized controlled trial in primary stage III and IV ovarian cancer after interval cytoreductive surgery (FOCUS).. Journal of Clinical Oncology. 42(16_suppl). TPS5636–TPS5636. 2 indexed citations

Sajous, Christophe, et al.. (2021). Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives. Cancers. 13(19). 4840–4840. 19 indexed citations

Joly, Florence, Bernard Asselain, Anne Floquet, et al.. (2020). Multicentre randomized phase II trial of olaparib as maintenance therapy in platinum-sensitive advanced endometrial carcinoma: The GINECO-UTOLA study.. Journal of Clinical Oncology. 38(15_suppl). TPS6109–TPS6109. 4 indexed citations

Fayette, Jérôme, Laurence Digue, Céline Ségura‐Ferlay, et al.. (2019). Buparlisib (BKM120) in refractory head and neck squamous cell carcinoma harbouring or not a PI3KCA mutation: A phase II multicenter trial. Annals of Oncology. 30. v455–v455. 6 indexed citations

Ezzalfani, Monia, Audrey Emmanuelle Dugué, Caroline Mollévi, et al.. (2015). Le rôle des cohortes d’expansion dans les essais de phase I en cancérologie : des recommandations du HUB phase I. Bulletin du Cancer. 102(1). 73–82. 4 indexed citations

Gan, Hui, et al.. (2012). Assumptions of Expected Benefits in Randomized Phase III Trials Evaluating Systemic Treatments for Cancer. JNCI Journal of the National Cancer Institute. 104(8). 590–598. 74 indexed citations

You, Benoît, et al.. (2010). Consistency in reporting of primary endpoints (PEP) from registration to publication for modern randomized oncology phase III trials.. Journal of Clinical Oncology. 28(15_suppl). 6031–6031. 3 indexed citations

10.

Falandry, Claire, Marc Bonnefoy, Benoît You, & Gilles Freyer. (2007). [Metastatic prostate cancer treatment in the elderly].. PubMed. 94(7 Suppl). F89–96. 2 indexed citations

11.

You, Benoît, et al.. (2007). [Targeted therapies in oncology].. PubMed. 57(19). 2093–8. 1 indexed citations

12.

Guan, Rui, et al.. (2000). p53 and K-ras gene mutations in lung cancer of workers exposed to silica and asbestos. Lung Cancer. 29(1). 211–211. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact